All insiders
VE
Venker Eric
CEOPrimarily ROIV
0% buying100% selling
Total Trades
29
0 buys · 29 sells
Total Bought
$0
Total Sold
$104.70M
Companies
2
Buy Win Rate
—
insufficient data
Avg Buy Return*
—
Active
Oct 6, 2025 → Oct 20, 2026
Trade Volume by Year
Buy Sell
Top Traded Sectors
Pharmaceutical Preparations25
Biological Products, (No Diagnostic Substances)4
Most-Traded Stocks
 ROIVRoivant Sciences Ltd. | 25 | 0B / 25S | $104.11M |
 IMVTImmunovant, Inc. | 4 | 0B / 4S | $581.42K |
Trade History
| Oct 20, 2026 | ROIV | SELL | 14,144 | $35.42 | $500.98K |
| Oct 20, 2026 | ROIV | SELL | 185,856 | $35.09 | $6.52M |
| Oct 2, 2026 | IMVT | SELL | 3,506 | $34.11 | $119.59K |
| Sep 30, 2026 | ROIV | SELL | 200,000 | $36.62 | $7.32M |
| Aug 28, 2026 | ROIV | SELL | 33,818 | $36.44 | $1.23M |
| Aug 28, 2026 | ROIV | SELL | 166,182 | $35.63 | $5.92M |
| Jul 27, 2026 | ROIV | SELL | 200,000 | $34.95 | $6.99M |
| Jul 2, 2026 | IMVT | SELL | 3,092 | $38.48 | $118.98K |
| Jun 24, 2026 | ROIV | SELL | 46,234 | $33.51 | $1.55M |
| Jun 24, 2026 | ROIV | SELL | 153,766 | $33.05 | $5.08M |
| May 22, 2026 | ROIV | SELL | 200,000 | $30.27 | $6.05M |
| Apr 20, 2026 | ROIV | SELL | 200,000 | $29.59 | $5.92M |
| Apr 2, 2026 | IMVT | SELL | 1,409 | $24.60 | $34.66K |
| Apr 2, 2026 | IMVT | SELL | 12,820 | $24.04 | $308.19K |
| Mar 17, 2026 | ROIV | SELL | 200,000 | $28.24 | $5.65M |
| Feb 13, 2026 | ROIV | SELL | 200,000 | $26.49 | $5.30M |
| Jan 12, 2026 | ROIV | SELL | 200,000 | $21.92 | $4.38M |
| Dec 24, 2025 | ROIV | SELL | 75,000 | $22.53 | $1.69M |
| Dec 23, 2025 | ROIV | SELL | 200,000 | $22.45 | $4.49M |
| Dec 9, 2025 | ROIV | SELL | 200,000 | $20.85 | $4.17M |
| Nov 7, 2025 | ROIV | SELL | 200,000 | $20.22 | $4.04M |
| Oct 17, 2025 | ROIV | SELL | 118,418 | $17.06 | $2.02M |
| Oct 16, 2025 | ROIV | SELL | 318,282 | $17.05 | $5.43M |
| Oct 15, 2025 | ROIV | SELL | 414,683 | $16.93 | $7.02M |
| Oct 13, 2025 | ROIV | SELL | 20,727 | $16.25 | $336.81K |
1–25 of 29
Page 1 of 2
*Return = current share price vs the insider’s purchase price (buys only). Not the insider’s realized return. Informational only — not investment advice.